Zerkalin cutaneous solution 1% 30ml — Made in Croatia — Free Delivery

Clindamycin is a semi-synthetic derivative of lincomycin, an antibiotic obtained from a culture of Streptomyces lincolensis. It has bacteriostatic and bactericidal properties, depending on the concentration at the site of action and the sensitivity of microorganisms. Clindamycin inhibits protein synthesis in susceptible bacteria by binding to the 50S subunit of bacterial ribosomes, interrupting the early stages of protein synthesis. It is known that the spectrum of action of clindamycin in vitro and in vivo covers the majority of gram-positive bacteria, interrupting the early stages of protein synthesis. It is known that the spectrum of action of clindamycin in vitro and in vivo covers the majority of gram-positive bacteria, most anaerobic pathogens and protozoa. The preparation  is ineffective against Enterobacteriaceae, fungi and viruses. After topical application to the skin of a 1% solution of clindamycin hydrochloride, the growth of sensitive bacteria, especially the anaerobes Propionibacterium acnes, which are in the sebaceous glands and follicles, is suppressed, and the concentration of free fatty acids (FFA) in the sebum is reduced. Such a decrease in the concentration of FFA in sebum is a consequence of the indirect suppression of microorganisms that produce lipase, which is necessary for the conversion of triglycerides to FFA, or a direct consequence of a decrease in the production of lipase by microorganisms. In addition to lipases, Propionibacterium acnes produce proteases, hyaluronidases and chemotoxic factors, which, together with comedogenic FFA, are responsible for the development of inflammatory lesions (papules, pustules, nodes, cysts) in acne. Therefore, for the development of the effect of local application of clindamycin in patients with acne, both antibacterial and anti-inflammatory actions are important (in which inhibition of leukocyte chemotaxis plays an important role).

It is known that in a specially created in vitro model of human skin, after application of clindamycin hydrochloride (labeled with a radioisotope), almost 10% of the dose is absorbed by the stratum corneum. Clindamycin penetrates well into inflammatory lesions after topical application. The bioavailability of clindamycin after application to the skin is approximately 7.5%.

Clinical characteristics.

Treatment of common acne.

Active substance: clindamycin;

1 ml of solution contains clindamycin - 10 mg, in the form of clindamycin hydrochloride;

excipients: ethanol 96%, propylene glycol, purified water.

Contraindicated in patients with a history of hypersensitivity to preparations containing clindamycin or lincomycin, Crohn's disease, ulcerative colitis or colitis associated with the use of antibiotics.

Interaction with other medicinal products and other types of interactions.

Clindamycin has the ability to block neuromuscular transmission, which can lead to an increase in the action of other preparations with similar properties. therefore, it should be used with caution in patients receiving such preparations. there is cross-resistance between clindamycin and lincomycin. antagonism between erythromycin and clindamycin has also been noted.

When clindamycin is applied topically, the antibiotic is absorbed from the skin surface. with external and systemic use of clindamycin, diarrhea, bloody diarrhea and colitis (in particular pseudomembranous colitis) have been reported.

It is known that the main cause of the development of colitis associated with the use of antibiotics is the toxin produced by Clostridia. Colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be accompanied by the discharge of blood and mucus. Pseudomembranous colitis can be diagnosed with endoscopic examination. Stool culture for Clostridium difficile (C. difficile) and stool analysis for C. difficile toxin can help diagnose this disease.